| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
1-Boc-DL-Pyroglutamic acid ethyl ester does not have a specific pharmacological target as it is a protected amino acid derivative used as a synthetic intermediate. Its function is to serve as a building block for the synthesis of peptides and pharmaceutical compounds. The Boc protecting group is used to selectively protect the amine functionality during peptide synthesis, preventing unwanted side reactions. The ethyl ester protecting group protects the carboxylic acid, allowing for selective deprotection and functionalization. Pyroglutamic acid derivatives are found in various biologically active peptides and natural products. The compound is used in medicinal chemistry for the synthesis of drug candidates and chemical probes. The compound's utility lies in its role as a synthetic intermediate rather than as a bioactive molecule itself.
|
|---|---|
| ln Vitro |
In vitro, 1-Boc-DL-Pyroglutamic acid ethyl ester is used as a synthetic intermediate in peptide synthesis and medicinal chemistry. The compound is used to introduce pyroglutamic acid residues into peptides and peptide-like molecules. Pyroglutamic acid is found in various biologically active peptides and is important for the stability and activity of these compounds. The Boc protecting group allows for the selective incorporation of the amino acid into peptide chains using standard solid-phase or solution-phase peptide synthesis techniques. The ethyl ester group can be selectively removed to allow for further functionalization or conjugation. The compound is used in the synthesis of pharmaceutical compounds and chemical probes for biological research. Its utility lies in its role as a versatile building block for organic synthesis.
|
| ln Vivo |
In vivo, 1-Boc-DL-Pyroglutamic acid ethyl ester is not used as a therapeutic agent but as a synthetic intermediate for the preparation of pharmaceutical compounds. The compound itself is not biologically active and is used solely as a chemical building block. The compound may be used in the synthesis of drug candidates that contain pyroglutamic acid moieties. Pyroglutamic acid derivatives have been studied for various biological activities, including neuroprotective, antioxidant, and anti-inflammatory effects. However, 1-Boc-DL-Pyroglutamic acid ethyl ester is a protected precursor that requires deprotection to yield the active compound. The compound is intended for research use only and is not approved for clinical use. Its role is limited to chemical synthesis and drug discovery.
|
| Enzyme Assay |
In vitro synthetic procedures using 1-Boc-DL-Pyroglutamic acid ethyl ester typically involve standard peptide synthesis techniques. The compound is dissolved in appropriate solvents such as DMF, DCM, or THF for coupling reactions. In solid-phase peptide synthesis, the compound is activated using coupling reagents such as HATU, HOBt, or DIC and coupled to resin-bound peptides. The Boc protecting group is removed using TFA or other acidic conditions. The ethyl ester is removed by hydrolysis using base such as NaOH or LiOH. The compound's purity and identity are confirmed by HPLC and NMR spectroscopy. The compound is typically stored at room temperature or 4°C. For long-term storage, the compound should be kept in a dry place and protected from moisture.
|
| Cell Assay |
Cell-based assays using 1-Boc-DL-Pyroglutamic acid ethyl ester are not typical as the compound is a synthetic intermediate rather than a bioactive molecule. However, the compound may be used to synthesize peptides or small molecules that are tested in cell-based assays. The compound itself would not be expected to have significant biological activity due to the presence of the protecting groups. For studies involving pyroglutamic acid derivatives, the protected compound would be deprotected to yield the active molecule before testing. The compound's solubility in organic solvents makes it suitable for use in organic synthesis. The compound is not typically used directly in cell culture experiments. Its role is limited to chemical synthesis and drug discovery.
|
| Animal Protocol |
In vivo animal experiments using 1-Boc-DL-Pyroglutamic acid ethyl ester are not typical as the compound is a synthetic intermediate rather than a therapeutic agent. The compound may be used in the synthesis of drug candidates that are subsequently tested in animal models. The compound itself is not administered to animals for therapeutic purposes. Its role is limited to chemical synthesis and drug discovery. The compound's pharmacokinetic and toxicity properties have not been characterized as it is not intended for in vivo use. The compound is intended for research use only and is not approved for clinical use. Standard laboratory safety precautions should be followed when handling the compound.
|
| ADME/Pharmacokinetics |
1-Boc-DL-Pyroglutamic acid ethyl ester has a molecular weight of approximately 257.28 g/mol and the formula C12H19NO5. The compound is soluble in organic solvents such as DMF, DCM, THF, and methanol. For long-term storage, the compound is kept at room temperature or 4°C in a dry place, protected from moisture. The compound is stable under normal storage conditions. The Boc protecting group can be removed under acidic conditions (e.g., TFA), and the ethyl ester can be removed by hydrolysis (e.g., NaOH). The compound is used as an intermediate in the synthesis of peptides and pharmaceutical compounds. Its purity and identity are confirmed by HPLC and NMR spectroscopy. The compound is intended for research use only and is not approved for clinical use.
|
| Toxicity/Toxicokinetics |
The toxicity of 1-Boc-DL-Pyroglutamic acid ethyl ester has not been extensively characterized as the compound is a synthetic intermediate rather than a therapeutic agent. The compound is intended for research use only and is not for human use. Standard laboratory safety precautions should be followed when handling the compound, including the use of gloves and eye protection. The compound may cause irritation to skin, eyes, and respiratory tract upon contact. Inhalation of dust should be avoided. The compound is not classified as a highly toxic substance but should be handled with appropriate care. Safety data sheets recommend standard handling procedures for research chemicals. The compound's toxicity in vivo has not been studied as it is not intended for in vivo use. The compound should be handled in a well-ventilated area.
|
| References | |
| Additional Infomation |
1-Boc-DL-Pyroglutamic acid ethyl ester (CAS 251924-83-1) is a protected amino acid derivative used in peptide synthesis and medicinal chemistry. It has the molecular formula C12H19NO5 and a molecular weight of approximately 257.28 g/mol. The compound contains a tert-butyloxycarbonyl (Boc) protecting group on the nitrogen atom and an ethyl ester protecting group on the carboxylic acid. Pyroglutamic acid (5-oxoproline) is a cyclic amino acid formed from glutamic acid by cyclization. The compound is used as an intermediate in the synthesis of peptides and pharmaceutical compounds. The Boc group is commonly used to protect amines during peptide synthesis and can be removed under acidic conditions. The ethyl ester group protects the carboxylic acid and can be removed by hydrolysis. The compound is soluble in organic solvents such as DMF, DCM, THF, and methanol. The compound is intended for research use only and is not approved for clinical use. It is typically stored at room temperature or 4°C in a dry place, protected from moisture.
|
| Molecular Formula |
C12H19NO5
|
|---|---|
| Molecular Weight |
257.282963991165
|
| Exact Mass |
257.126
|
| CAS # |
251924-83-1
|
| PubChem CID |
3648390
|
| Appearance |
Light yellow to yellow viscous liquid
|
| LogP |
1.715
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
18
|
| Complexity |
358
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)C1CCC(=O)N1C(=O)OC(C)(C)C
|
| InChi Key |
YWWWGFSJHCFVOW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H19NO5/c1-5-17-10(15)8-6-7-9(14)13(8)11(16)18-12(2,3)4/h8H,5-7H2,1-4H3
|
| Chemical Name |
1-O-tert-butyl 2-O-ethyl 5-oxopyrrolidine-1,2-dicarboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8868 mL | 19.4341 mL | 38.8682 mL | |
| 5 mM | 0.7774 mL | 3.8868 mL | 7.7736 mL | |
| 10 mM | 0.3887 mL | 1.9434 mL | 3.8868 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
